Page last updated: 2024-11-08

n-phenylacrylamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-phenylacrylamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID221792
CHEMBL ID2086477
SCHEMBL ID13341546
SCHEMBL ID81209
MeSH IDM0559944

Synonyms (38)

Synonym
nsc-6857
acrylanilide
2210-24-4
2-propenamide, n-phenyl-
nsc6857
AQ-917/42754051
n-phenylacrylamide
n-phenylacrylamide, 99%
AKOS003287375
n-phenylprop-2-enamide
EN300-64470
CHEMBL2086477 ,
bdbm50420529
asylanilide
SCHEMBL13341546
SCHEMBL81209
n-phenyl acrylamide
n1-phenylacrylamide
n-phenylacrylateamide
n-phenylacrylamide #
P2093
nsc 6857
a2aqj9fv2g ,
ec 606-936-1
unii-a2aqj9fv2g
DTXSID60278268
mfcd00080617
A878726
FT-0733718
CS-W019368
DS-6577
SY052499
Z440633536
AMY39198
n-acryloylaniline
n-phenyl-2-propenamide
25620-46-6
HY-W018582
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)IC50 (µMol)43.00000.04502.67428.0000AID683883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
gene expressionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
dopamine secretionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
chromatin remodelingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
proteolysisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptide cross-linkingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
protein deaminationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
negative regulation of endoplasmic reticulum calcium ion concentrationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
regulation of apoptotic processProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of apoptotic processProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
apoptotic cell clearanceProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of GTPase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of cell adhesionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of neurogenesisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of small GTPase mediated signal transductionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of mitochondrial calcium ion concentrationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
bone developmentProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
branching involved in salivary gland morphogenesisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
salivary gland cavitationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cellular response to cocaineProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cellular response to dopamineProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of sprouting angiogenesisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cellular response to serotoninProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
regulation of apoptotic cell clearanceProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
protein-glutamine gamma-glutamyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
calcium ion bindingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
protein bindingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
GTP bindingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptidase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
protein-glutamine glutaminase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
histone serotonyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
histone dopaminyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptide noradrenalinyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptide histaminyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
collagen-containing extracellular matrixProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
nucleusProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
mitochondrionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
endoplasmic reticulumProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cytosolProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
plasma membraneProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
focal adhesionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
extracellular matrixProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
perinuclear region of cytoplasmProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
collagen-containing extracellular matrixProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
extracellular exosomeProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
chromatinProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
nucleosomeProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
mitochondrionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1594609Drug reactivity against cysteine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID1160973Inhibition of wild-type Escherichia coli MurD compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1677069GSH reactivity in pH 7.4 phosphate buffer assessed as half life at 1 uM in presence of glutathione measured up to 120 mins by LC/MS analysis2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Systematic Study of the Glutathione Reactivity of
AID1594611Drug reactivity against cysteine in PBS buffer assessed as rate constant by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID683884Irreversible inhibition of human recombinant TG2 assessed as ratio of Kinact to Ki2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
AID1594613Reversible drug reactivity against cysteine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID1160977Induction of covalent MurA enzyme adduct formation preincubated with UNAG substrate for 10 mins compound treated at 300 uM after 1 hr by ESI-MS analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160975Inhibition of wild-type Escherichia coli MurF compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160981Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CellTiter-Blue assay2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID770074Aqueous solubility of the compound2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID1677068GSH reactivity in pH 7.4 phosphate buffer assessed as pseudo first-order rate constant at 1 uM in presence of glutathione measured up to 120 mins by LC/MS analysis2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Systematic Study of the Glutathione Reactivity of
AID1160972Inhibition of wild-type Escherichia coli MurC compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160983GSH reactivity of the compound assessed as adducts formation meaured over 3 hrs by RP-HPLC analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160974Inhibition of wild-type Escherichia coli MurE compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1170688GSH reactivity assessed as reaction half life through transition state modeling at pH 7.42014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors.
AID1677067GSH reactivity in pH 7.4 phosphate buffer assessed as change in gibbs free energy at 1 uM in presence of glutathione measured up to 120 mins by LC/MS analysis2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Systematic Study of the Glutathione Reactivity of
AID1553480Half life of the compound2019Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
AID1469830Thiol reactivity of the compound in PBS/DMSO buffer assessed as pseudo-first order rate constant for adduct formation2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.
AID683883Inhibition of human recombinant TG2 by fluorescent transamidation assay2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
AID1160967Inhibition of Bovine thrombin using Boc-Val-Pro-Arg-AMC as substrate compound preincubated at 25 uM for 15 mins by fluorescence assay2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160971Inhibition of wild-type Escherichia coli MurB compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160976GSH reactivity of the compound assessed as adducts formation by RP-HPLC analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160980Induction of covalent MetAP enzyme adduct formation at 300 uM after 1 hr by ESI-MS analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID770037Chemical stability in phosphate buffer at pH 7.4 at 50 uM by LC-MS analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID1170691Reactivity of covalent reactive group using GSH reaction assessed as pseudo-first-order reaction at 37 degC by mass spectrometry2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors.
AID1594614Reversible drug reactivity against serine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID1160965Inhibition of Dengue virus serotype 2 NS2B-NS3 protease at 50 uM2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1594610Drug reactivity against serine in PBS buffer by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID770073Half life in phosphate buffer at pH 7.4 at 50 uM by LC-MS analysis in presence of glutathione2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID1517970Inhibition of human FBPase expressed in Escherichia coli BL21 (DE3) at 500 uM using FBP as substrate incubated for 5 mins by malachite green dye based spectrophotometry relative to control2019European journal of medicinal chemistry, Dec-15, Volume: 184Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects.
AID1160968Inhibition of Escherichia coli MetAP at 25 uM after 20 mins by HPLC analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160969Inhibition of human MetAP at 25 uM after 20 mins by HPLC analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1652358GSH reactivity of the compound in presence of GSH assessed as half life using DNTB2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach.
AID1160970Inhibition of wild-type Escherichia coli MurA compound preincubated for 10 mins before substrate addition at 25 uM measured after 15 mins by LC-MS method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1594612Drug reactivity against cysteine in PBS buffer assessed as half life by NMR assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Characterising covalent warhead reactivity.
AID1160979Induction of covalent MurE enzyme adduct formation preincubated with UNAG substrate for 10 mins compound treated at 300 uM after 1 hr by ESI-MS analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
AID1160966Inhibition of West Nile virus NS2B-NS3 protease at 50 uM2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's14 (73.68)24.3611
2020's5 (26.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.19 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]